Table 1 Demographic features of the patients’ data
N = 152 | Descriptive |
|---|---|
Eye (right, %) | 79 (51.9%) |
Sex (male, %) | 82 (53.3%) |
Age (mean, SD) | 73.6 (SD 10.72) |
Pathology (number,%) | |
AMD | 85 (55.9%) |
RVO | 26 (17.1%) |
DME | 24 (15.8%) |
Myopia | 4 (2.6%) |
Others | 13 (8.6%) |
Snellen VA (mean, SD) | 0.5 (SD 1.29) |
Follow-up time in months (mean, SD) | 34.68 (SD 30.74) |
IVI number (mean, SD) | 1544 (10.1, SD 8.45) |
Aflibercept number (mean, SD) | 876 (5.8, SD 5.94) |
Ranibizumab number (mean, SD) | 553 (3.6, SD 5.77) |
Bevacizumab number (mean, SD) | 86 (0.6, SD 1.53) |
Dexamethasone implant number (mean, SD) | 29 (0.2, SD 0.99) |
Presence of PVD (n, %) | 100 (65.8%) |
Symptoms | |
Scotoma (n, %) | 30 (19.7%) |
Metamorphopsia (n, %) | 52 (34.2%) |
Floaters (n, %) | 60 (39.5%) |
IOP (mean, SD) | 16.07 (SD 8.81) |